Physician profile
David W Allen
NPI 1316933955
$3,618.40
in general payments reported to CMS, 2019-2025
27 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $458 · 2021: $542 · 2022: $597 · 2023: $340 · 2024: $271 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $582.10 | 2019-2024 | |
| Novo Nordisk INC | $383.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $265.02 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $262.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $233.54 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $219.92 | 2019-2022 | |
| Lilly USA, LLC | $208.33 | 2019-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $169.46 | 2023-2025 | Gemtesa |
| Tactile Systems Technology INC | $150.19 | 2023 | Entre Plus, Flexitouch Plus |
| Abbvie INC. | $143.49 | 2020-2024 | Ubrelvy |
| Astellas Pharma US INC | $136.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.11 | 2019-2022 | |
| Exact Sciences Corporation | $118.38 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $77.85 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.66 | 2019-2022 | |
| Allergan, INC. | $58.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.79 | 2022 | |
| Amarin Pharma, INC. | $50.98 | 2019 | |
| Eisai INC. | $49.98 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $31.08 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $27.52 | 2019 | |
| Irhythm Technologies, INC. | $26.80 | 2022 | |
| Neuronetics, INC. | $25.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.54 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.31 | 2021 | |
| Daiichi Sankyo INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.